Education
About Us
Working with TipRanks
Follow Us
CG Oncology, Inc. (CGON)
NASDAQ:CGON
CGON Stock Chart & Stats
$41.93
-$0.55(-1.77%)
At close: 4:00 PM EST
$41.93
-$0.55(-1.77%)
Day’s Range― - ―
52-Week Range$14.80 - $46.01
Previous Close$30.46
Volume740.02K
Average Volume (3M)803.86K
Market Cap
$3.38B
Enterprise Value$2.42B
Total Cash (Recent Filing)$680.26M
Total Debt (Recent Filing)$7.24M
Price to Earnings (P/E)―
Beta1.80
Next Earnings
Mar 27, 2026EPS Estimate
-0.6Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.57
Shares Outstanding80,666,176
10 Day Avg. Volume806,757
30 Day Avg. Volume803,857
Financial Highlights & Ratios
PEG Ratio-0.53
Price to Book (P/B)2.44
Price to Sales (P/S)1573.67
P/FCF Ratio-22.70
Enterprise Value/Market Cap0.71
Enterprise Value/Revenue1.11K
Enterprise Value/Gross Profit5.48K
Enterprise Value/Ebitda-14.66
Forecast
1Y Price Target
$74.55Price Target Upside77.80% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Differentiated Clinical ProfileAnalyst points to consistently high response rates, durable benefit and a clean safety profile in earlier studies, which increase the probability of favorable pivotal results and fast adoption by urologists.
Regulatory And Market OpportunityAnalyst notes the randomized registrational design testing the therapy versus surveillance in intermediate‑risk NMIBC offers a clear regulatory pathway to become the first approved adjuvant option for a large unmet patient population.
Trial Enrollment MomentumAnalyst highlights unusually rapid and fully enrolled pivotal trial across many sites as evidence of strong physician and patient interest that could accelerate clinical milestones and support commercial momentum.
Bears Say
Event-driven Volatility From Trial ReadoutAnalyst cautions that the added pivotal readout increases event-driven volatility, and a disappointing clinical outcome could trigger a sharp share-price decline.
Financial Risk And Financing PressureAnalyst warns that elevated cash burn combined with higher short interest raises financing risk and the potential for dilution if the company must access additional capital.
CG Oncology, Inc. News
CGON FAQ
What was CG Oncology, Inc.’s price range in the past 12 months?
CG Oncology, Inc. lowest stock price was $14.80 and its highest was $46.01 in the past 12 months.
What is CG Oncology, Inc.’s market cap?
CG Oncology, Inc.’s market cap is $3.38B.
When is CG Oncology, Inc.’s upcoming earnings report date?
CG Oncology, Inc.’s upcoming earnings report date is Mar 27, 2026 which is in 74 days.
How were CG Oncology, Inc.’s earnings last quarter?
CG Oncology, Inc. released its earnings results on Nov 14, 2025. The company reported -$0.57 earnings per share for the quarter, missing the consensus estimate of -$0.559 by -$0.011.
Is CG Oncology, Inc. overvalued?
According to Wall Street analysts CG Oncology, Inc.’s price is currently Undervalued.
Does CG Oncology, Inc. pay dividends?
CG Oncology, Inc. does not currently pay dividends.
What is CG Oncology, Inc.’s EPS estimate?
CG Oncology, Inc.’s EPS estimate is -0.6.
How many shares outstanding does CG Oncology, Inc. have?
CG Oncology, Inc. has 80,666,176 shares outstanding.
What happened to CG Oncology, Inc.’s price movement after its last earnings report?
CG Oncology, Inc. reported an EPS of -$0.57 in its last earnings report, missing expectations of -$0.559. Following the earnings report the stock price went up 8.607%.
Which hedge fund is a major shareholder of CG Oncology, Inc.?
Currently, no hedge funds are holding shares in CGON
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CG Oncology, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$74.55 (77.80% Upside)
$74.55 (77.80% Upside)
Blogger Sentiment
Bullish
CGON Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 57.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days <0.1%
Last 30 Days ▲ 14.5%
Last 30 Days ▲ 14.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
37.65%
12-Months-Change
Fundamentals
Return on Equity
-24.74%
Trailing 12-Months
Asset Growth
32.12%
Trailing 12-Months
Company Description
CG Oncology, Inc.
CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.
CGON Stock 12 Month Forecast
Average Price Target
$74.55
▲(77.80% Upside)
Technical Analysis
Cogent Biosciences
―
IDEAYA Biosciences
―
Arcutis Biotherapeutics
―
Beam Therapeutics
―
Disc Medicine
―
Ownership Overview
10.61% Insiders
21.98% Mutual Funds
42.45% Other Institutional Investors
11.44% Public Companies and
Individual Investors